Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer
ACTIVE_NOT_RECRUITING
Status
Conditions
Interventions
- DRUG: degarelix
- DRUG: enzalutamide
- DRUG: trametinib
- DRUG: dasatinib
Sponsor
Jonsson Comprehensive Cancer Center
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]